A major new campaign to boost the uptake of and patient access to biosimilars has been launched by Sandoz, under the title of Act4Biosimilars. The initiative has a goal of increasing biosimilar adoption by at least 30% in at least 30 countries by 2030.
Sandoz Launches Global Biosimilars Initiative
‘Act4Biosimilars’ Aims To Increase Adoption By At Least 30% In 30 Countries By 2030
Sandoz has launched a global campaign to increase uptake of biosimilars, under the banner of Act4Biosimilars. The initiative aims to increase the adoption of biosimilars by at least 30% in at least 30 countries by 2030.

More from Biosimilars
More from Products
Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.
With discounts reaching up to 90%, ustekinumab biosimilars have eroded originator Stelara’s sales as expected. In its latest quarterly biosimilar market report, Samsung Bioepis also analyzed the latest regulatory steps to streamline biosimilar development.
As its need for development resources declines, Iconovo is cutting staff to save money as it moves to the commercialization stage for its portfolio of off-patent inhaled products.